• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Enhanced patient support services improve patient persistence with multiple sclerosis treatment
【24h】

Enhanced patient support services improve patient persistence with multiple sclerosis treatment

机译：增强的患者支持服务可通过多发性硬化症治疗改善患者的持久性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Subcutaneous interferon beta-1a (sc IFN β-1a) therapy (44 μg or 22 μg, three times weekly) improves relapse rates and disability progression in patients with relapsing multiple sclerosis (MS). While early treatment with disease-modifying drugs may maximize therapeutic benefit, patients with low adherence or long treatment gaps are at increased risk of relapse. MySupport is an industry-sponsored program that provides support to patients with MS who have been prescribed sc IFN β-1a in the UK or Republic of Ireland (ROI), via telephone and text messaging, website access, and (in some cases) face-to-face support from a dedicated MySupport Nurse. The aim of this audit was to assess if the MySupport program in the ROI could improve persistence to sc IFN β-1a therapy.Methods: Anonymized data were supplied retrospectively from the MySupport program, for ROI patients who were registered in January 2010 to receive sc IFN β-1a three times weekly. Patients were recorded as “new” at their first drug delivery; “active”, if they continued to receive scheduled deliveries; “interrupted”, if their medication delivery was halted; or “stopped”, if no deliveries were made for 12 months. The number of “active” patients was recorded monthly for 24 months. Results were compared with data from UK patients with MS, who were receiving National Health Service (NHS) support only, or this support plus MySupport.Results: A greater proportion of ROI patients receiving MySupport (compared against UK patients receiving NHS support only) were on treatment at 12 months (87.8% versus 79.3%) and at 24 months (76.2% versus 61.8%). The odds of being on treatment were significantly greater, at all time points, for ROI patients receiving MySupport, versus UK patients receiving NHS support only (P<0.0001).Conclusion: A personalized support program, utilizing one-to-one nursing support and additional support materials, can increase the probability of patients with MS remaining on disease-modifying drug treatment.
机译：背景：皮下干扰素β-1a（sc IFNβ-1a）治疗（44μg或22μg，每周3次）可改善复发性多发性硬化症（MS）患者的复发率和残疾进展。虽然早期使用缓解疾病的药物可以最大程度地提高治疗效果，但依从性低或治疗间隔长的患者复发的风险更高。 MySupport是一项由行业赞助的计划，该计划通过电话和短信，网站访问以及（在某些情况下）面孔为在英国或爱尔兰共和国（ROI）开具sc IFNβ-1a处方的MS患者提供支持专门的MySupport Nurse提供的面对面支持。这项审核的目的是评估ROI中的MySupport计划是否可以改善对sc IFNβ-1a治疗的持久性。方法：从MySupport计划中回顾性提供匿名数据，用于2010年1月注册接受sc的ROI患者每周三次干扰素β-1a。患者在首次给药时被记录为“新患者”。如果他们继续收到预定的交货，则为“活跃”; “中断”，如果他们的药物输送停止了;或“停止”（如果12个月内没有交货）。每月记录“活跃”患者的数量，持续24个月。将结果与仅接受国家卫生服务（NHS）支持或此项支持加上MySupport的英国MS患者的数据进行比较。结果：接受MySupport的ROI患者中有更大比例（与仅接受NHS支持的英国患者相比）分别在12个月（87.8％对79.3％）和24个月（76.2％对61.8％）时接受治疗。与仅接受NHS支持的英国患者相比，接受MySupport的ROI患者在所有时间点接受治疗的几率均显着更高（P <0.0001）。结论：个性化支持计划，利用一对一的护理支持和额外的支持材料，可以增加MS患者继续接受改善疾病药物治疗的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号